# US 2026/0048111 A1 · Pharmaceutical Composition, Preparation Method and Use Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0048111 A1
- Document ID: US20260048111A1
- Status: Published application
- Kind: A1
- Application number: 19/369,382
- Filed: 2025-10-27
- Published: 2026-02-19
- Earliest claimed: 2023-04-27
- Assignees: PuGong Biotech (Hangzhou) Co., Ltd.
- Applicants: PuGong Biotech (Hangzhou) Co., Ltd.
- Inventors: Jian CHANG; Lei CHEN; Wenbin GAO
- Web page: https://patentgrep.com/patent/US20260048111A1

## CPC

- A61K 39/085: Staphylococcus
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/07: Retinol compounds, e.g. vitamin A (retinoic acids A61K31/203)
- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61K 39/0016: {Combination vaccines based on diphtheria-tetanus-pertussis}
- A61K 39/0275: {Salmonella}
- A61K 39/099: {Bordetella}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K 47/38: Cellulose; Derivatives thereof
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- A61K 2039/5158: {Antigen-pulsed cells, e.g. T-cells}
- A61K 2039/55544: {Bacterial toxins}
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- A61K 2039/585: {wherein the target is cancer}
- A61K 2039/812: {Breast}
- A61K 2039/844: {Liver}
- A61K 2039/852: {Pancreas}
- A61K 2039/86: {Lung}
- A61K 2039/876: {Skin, melanoma}
- A61K 2039/892: {Reproductive system [uterus, ovaries, cervix, testes]}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present disclosure relates to the technical field of medicine, and in particular to a pharmaceutical composition, preparation method and use thereof. The pharmaceutical composition includes a first active ingredient, a second active ingredient, and a pharmaceutically acceptable carrier or excipient. The first active ingredient is a microbial agent, including one or more of Staphylococcus aureus, Bordetella pertussis, diphtheria toxoid, tetanus toxoid, Salmonella typhi, and Salmonella paratyphi. The second active ingredient includes polyinosinic acid, polycytidylic acid, and vitamin. The pharmaceutical composition of the present disclosure pertains to an artificial active immunotherapy for tumors. It can “stimulate” the entire immune system, making the therapy of using bacteria to activate the human immune system to kill cancer cells highly stable and reliable. This composition can significantly save and prolong the lives of cancer patients while exhibiting extremely high safety, minimal toxic side effects, and low production costs.

## Claims

### Claim 1

A pharmaceutical composition, comprising a first active ingredient, a second active ingredient, and a pharmaceutically acceptable carrier or excipient; wherein the first active ingredient is a microbial agent comprising one or more of Staphylococcus aureus, Bordetella pertussis, diphtheria toxoid, tetanus toxoid, Salmonella typhi, and Salmonella paratyphi; wherein the second active ingredient comprises polyinosinic acid, polycytidylic acid, and vitamin A.

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the microbial agent is an inactivated preparation, and/or the microbial agent is a liquid preparation or a solid preparation.

### Claim 3 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition further comprises one or more of the following:
1) based on a total volume of the pharmaceutical composition, a concentration of Staphylococcus aureus is in a range of 2×107-3×109 CFU/mL;
2) based on the total volume of the pharmaceutical composition, a concentration of Bordetella pertussis is in a range of 7×107-9×109 CFU/mL;
3) based on the total volume of the pharmaceutical composition, a concentration of the diphtheria toxoid is in a range of 1 LF-5 LF/mL;
4) based on the total volume of the pharmaceutical composition, a concentration of the tetanus toxoid is in a range of 0.1 LF-5 LF/mL;
5) based on the total volume of the pharmaceutical composition, a concentration of Salmonella typhi is in a range of 1.5×106-5×108 CFU/mL;
6) based on the total volume of the pharmaceutical composition, a concentration of Salmonella paratyphi is in a range of 1×106-3×108 CFU/mL.

### Claim 4 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the Salmonella paratyphi is one or more of Salmonella paratyphi A, Salmonella paratyphi B, and Salmonella paratyphi C.

### Claim 5 (depends on 4)

The pharmaceutical composition according to claim 4, wherein the Salmonella paratyphi is one or more of Salmonella paratyphi A and Salmonella paratyphi B.

### Claim 6 (depends on 5)

The pharmaceutical composition according to claim 5, wherein based on a total volume of the pharmaceutical composition, a concentration of Salmonella paratyphi A is in a range of 0.1×107-8×107 CFU/mL, and/or a concentration of Salmonella paratyphi B is in a range of 0.1×107-8×107 CFU/mL.

### Claim 7 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the polyinosinic acid and the polycytidylic acid are, respectively, selected from a polymer formed solely from inosinic acid, a polymer formed solely from cytidylic acid, and a copolymer of inosinic acid and cytidylic acid.

### Claim 8 (depends on 7)

The pharmaceutical composition according to claim 7, wherein when the polyinosinic acid and the polycytidylic acid are a polymer formed solely from inosinic acid and a polymer formed solely from cytidylic acid, respectively, a mass ratio of the polyinosinic acid to the polycytidylic acid is in a range of 1:0.1-1:10.

### Claim 9 (depends on 8)

The pharmaceutical composition according to claim 8, wherein the mass ratio of the polyinosinic acid to the polycytidylic acid is 1:1.

### Claim 10 (depends on 9)

The pharmaceutical composition according to claim 9, wherein based on a total volume of the pharmaceutical composition, concentrations of the polyinosinic acid and the polycytidylic acid are each less than 0.5 g/100 mL.

### Claim 11 (depends on 10)

The pharmaceutical composition according to claim 10, wherein the concentrations of the polyinosinic acid and the polycytidylic acid are each in a range of 0.01 g/100 mL-0.5 g/100 mL.

### Claim 12 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the vitamin A is vitamin A1 and/or vitamin A2.

### Claim 13 (depends on 12)

The pharmaceutical composition according to claim 12, wherein based on a total volume of the pharmaceutical composition, a concentration of the vitamin A is less than 1 g/100 mL.

### Claim 14 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the pharmaceutically acceptable carrier or excipient comprises sodium carboxymethyl cellulose, aluminum stearate, Tween 80, lecithin, soybean oil, dextran, fat emulsion, and water.

### Claim 15 (depends on 14)

The pharmaceutical composition according to claim 14, wherein the aluminum stearate is aluminum monostearate or aluminum distearate.

### Claim 16 (depends on 15)

The pharmaceutical composition according to claim 15, wherein the pharmaceutical composition further comprises one or more of the following
based on a total volume of the pharmaceutical composition, a concentration of the sodium carboxymethyl cellulose in the pharmaceutically acceptable carrier or excipient is less than 2 g/100 mL;
based on the total volume of the pharmaceutical composition, a concentration of the aluminum stearate in the pharmaceutically acceptable carrier or excipient is less than 3 g/100 mL;
based on the total volume of the pharmaceutical composition, a concentration of the Tween 80 in the pharmaceutically acceptable carrier or excipient is less than 1 mL/100 mL;
based on the total volume of the pharmaceutical composition, a concentration of the lecithin in the pharmaceutically acceptable carrier or excipient is more than 50 mg/100 mL;
based on the total volume of the pharmaceutical composition, a concentration of the soybean oil in the pharmaceutically acceptable carrier or excipient is less than 15 mL/100 mL;
based on the total volume of the pharmaceutical composition, a concentration of the dextran in the pharmaceutically acceptable carrier or excipient is less than 10 g/100 mL;
based on the total volume of the pharmaceutical composition, a concentration of the fat emulsion in the pharmaceutically acceptable carrier or excipient is more than 10 mL/100 mL.

### Claim 17 (depends on 16)

The pharmaceutical composition according to claim 16, wherein the pharmaceutical composition further comprises one or more of the following:
based on the total volume of the pharmaceutical composition, the concentration of the sodium carboxymethyl cellulose in the pharmaceutically acceptable carrier or excipient is in a range of 0.2-2 g/100 mL;
based on the total volume of the pharmaceutical composition, the concentration of the aluminum stearate in the pharmaceutically acceptable carrier or excipient is in a range of 0.3-3 g/100 mL;
based on the total volume of the pharmaceutical composition, the concentration of the Tween 80 in the pharmaceutically acceptable carrier or excipient is in a range of 0.1-1 mL/100 mL;
based on the total volume of the pharmaceutical composition, the concentration of the lecithin in the pharmaceutically acceptable carrier or excipient is in a range of 50-2000 mg/100 mL;
based on the total volume of the pharmaceutical composition, the concentration of the soybean oil in the pharmaceutically acceptable carrier or excipient is in a range of 1-15 mL/100 mL;
based on the total volume of the pharmaceutical composition, the concentration of the dextran in the pharmaceutically acceptable carrier or excipient is in a range of 1-10 g/100 mL;
based on the total volume of the pharmaceutical composition, the concentration of the fat emulsion in the pharmaceutically acceptable carrier or excipient is in a range of 10-80 mL/100 mL.

### Claim 18 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is an injection.

### Claim 19 (depends on 1)

A method for treating, preventing, or diagnosing a disease, comprising: administering an effective amount of the pharmaceutical composition according to claim 1 to a subject in need thereof.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the disease is selected from cancer, arteriosclerosis, HPV infection, and atrophic gastritis; and the cancer is selected from liver cancer, lung cancer, melanoma, colorectal cancer, gastric cancer, ovarian cancer, cholangiocarcinoma, cervical cancer, pancreatic cancer, prostate cancer, sarcoma, and breast cancer.
